Compare Cytokinetics Inc (CYTK) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Robinhood Markets, Inc. — how do they compare? Cytokinetics Inc trades at $76.58 (market cap $10.63B), while Robinhood Markets, Inc. trades at $94.22 (market cap $84.86B). The key difference: Robinhood Markets, Inc. is far larger — about 8× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals.
| CYTK | HOOD | |
|---|---|---|
Market Cap | $10.63B | $84.86B |
Sector | Technology | Technology |
52-Week High | $87.26 | $152.46 |
52-Week Low | $34.31 | $65.16 |
Enterprise Value | $10.74B | $91.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Robinhood (HOOD) trades at $94.52, up 1.32% in 24 hours, with a bearish technical signal from moving averages and RSI near overbought levels. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.62 actual vs. $0.44 expected, and revenue growth of 32% year-over-year. Recent news highlights expansion into UK crypto services and product diversification, though technical indicators suggest caution amid high valuation multiples.
Outlook: Bullish fundamentals with robust revenue growth and profit margins, but elevated P/E of 41.76 poses valuation risk. Opportunities include international expansion and non-crypto revenue streams; risks involve competitive pressures and reliance on market volatility. Analyst consensus price target of $123.46 implies significant upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
